An interventional study of Enhanced Expiratory Rebreathing Space (EERS) Therapy and Automatic Positive Airway Pressure (APAP) Therapy in Complex Sleep Apnea and Cardiovascular Diseases (CVD), sponsored by Chinese Pulmonary Vascular Disease Research Group. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the effectiveness and safety of enhanced expiratory rebreathing space (EERS) therapy compared with conventional automatic positive airway pressure (APAP) therapy in patients with cardiovascular disease and complex sleep apnea (CompSA).
This is a prospective, single-center, randomized controlled trial involving 40 participants aged 18-75 years. Eligible participants will be randomly assigned to either the EERS group or the conventional APAP group in a 1:1 ratio. Participants in the EERS group will receive individualized EERS therapy guided by overnight sleep monitoring, while those in the control group will receive conventional APAP therapy.
Each participant will be followed for five weeks, including a one-week screening period, a two-week treatment period, and a two-week follow-up period. The primary outcome is the apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour of sleep, assessed after two weeks of treatment. Additional outcomes include other sleep-related breathing measures, cardiovascular health indicators, treatment adherence, comfort, and adverse events.
The findings may help determine whether EERS therapy is an effective and safe treatment option for complex sleep apnea in patients with cardiovascular disease.
1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 674 interventional studies indexed under Sleep Apnea Syndromes.
Browse Sleep Apnea Syndromes studies →Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Enhanced Expiratory Rebreathing Space (EERS) Therapy
Device: Automatic Positive Airway Pressure (APAP) Therapy
Participants will undergo individualized manual continuous positive airway pressure (CPAP) titration under overnight polysomnographic (PSG) monitoring. An enhanced expiratory rebreathing space (EERS) device will be connected between the patient interface and a single-level CPAP device to increase expiratory carbon dioxide rebreathing and stabilize respiratory control. End-tidal carbon dioxide (EtCO₂) will be monitored throughout titration. CPAP pressure will initially be set at 4-6 cmH₂O and manually adjusted by trained sleep technicians in increments of 1-2 cmH₂O to eliminate obstructive respiratory events. The lowest effective pressure will be selected for subsequent treatment. Participants will then receive home-based CPAP therapy combined with EERS for two weeks.
Participants will undergo conventional automatic positive airway pressure (APAP) titration during overnight sleep monitoring using a single-level noninvasive positive airway pressure device and a nasal or oronasal mask. The initial pressure range will be set at 4-18 cmH₂O. The device will automatically adjust airway pressure in response to obstructive respiratory events, including apnea, hypopnea, snoring, and airflow limitation. Sleep technicians will monitor respiratory signals, oxygen saturation, mask leakage, and treatment tolerance. Individualized treatment settings will be determined based on overnight titration results, followed by two weeks of home-based positive airway pressure therapy.
Apnea-Hypopnea Index (AHI) After Two Weeks of Treatment
The apnea-hypopnea index (AHI) will be measured during overnight sleep monitoring while participants receive their assigned positive airway pressure therapy after two weeks of treatment. AHI is defined as the total number of apnea and hypopnea events per hour of sleep. Respiratory events will be scored according to the American Academy of Sleep Medicine (AASM) criteria. Lower AHI values indicate fewer sleep-disordered breathing events.
Time frame: 2 weeks after initiation of treatment
Residual Central Apnea Index (CAI)
The residual central apnea index (CAI) will be assessed during overnight sleep monitoring while participants receive their assigned treatment. CAI is defined as the number of central apnea events per hour of sleep, with lower values indicating fewer central respiratory events.
Time frame: 2 weeks after initiation of treatment
Minimum Nocturnal Oxygen Saturation (SpO₂)
The lowest peripheral oxygen saturation (%) recorded during overnight sleep monitoring while participants receive their assigned treatment.
Time frame: 2 weeks after initiation of treatment
Oxygen Desaturation Index (ODI)
The number of oxygen desaturation events per hour of sleep, measured during overnight sleep monitoring after two weeks of treatment.
Time frame: 2 weeks after initiation of treatment
Time Spent With Oxygen Saturation Below 90% (T90)
The duration of time during overnight sleep monitoring in which peripheral oxygen saturation is below 90%.
Time frame: 2 weeks after initiation of treatment
Epworth Sleepiness Scale (ESS) Score
Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS), which ranges from 0 to 24. Higher scores indicate greater daytime sleepiness.
Time frame: 2 weeks after initiation of treatment
24-Hour Ambulatory Blood Pressure
Mean systolic and diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring.
Time frame: 2 weeks after initiation of treatment
24-Hour Ambulatory Electrocardiographic Parameters
Cardiovascular parameters assessed using 24-hour ambulatory ECG monitoring.
Time frame: 2 weeks after initiation of treatment
N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
Serum NT-proBNP concentration.
Time frame: 2 weeks after initiation of treatment
Average Nightly Positive Airway Pressure Usage
Average duration of device use per night, expressed in hours.
Time frame: During the 2-week intervention period
Patient-Ventilator Asynchrony
Occurrence of patient-ventilator asynchrony during treatment.
Time frame: During the 2-week intervention period
Ventilatory Comfort Visual Analog Scale (VAS) Score
Patient-reported comfort during positive airway pressure therapy.
Time frame: 2 weeks after initiation of treatment
Incidence of Adverse Events
The number and proportion of participants experiencing adverse events will be recorded during the two-week intervention period and the subsequent two-week follow-up period. Adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
Time frame: From initiation of treatment through 2 weeks after treatment completion
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.
Of 202 non-industry interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 60. This study's planned 11 months is below that.
Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Pulmonary Vascular Disease Research Group